Ventum Cap Mkts Weighs in on Cresco Labs FY2026 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF) – Analysts at Ventum Cap Mkts issued their FY2026 earnings estimates for Cresco Labs in a research note issued on Monday, November 11th. Ventum Cap Mkts analyst A. Semple forecasts that the company will post earnings of ($0.06) per share for the year. Ventum Cap Mkts has a “Strong-Buy” rating on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.16) per share.

CRLBF has been the topic of a number of other research reports. Needham & Company LLC reissued a “hold” rating on shares of Cresco Labs in a report on Monday, August 12th. Roth Capital upgraded Cresco Labs to a “strong-buy” rating in a report on Sunday. Two analysts have rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Cresco Labs presently has a consensus rating of “Buy” and a consensus target price of $2.50.

Cresco Labs Price Performance

Cresco Labs stock opened at $1.26 on Wednesday. The firm has a fifty day simple moving average of $1.59 and a two-hundred day simple moving average of $1.71. The company has a debt-to-equity ratio of 1.76, a current ratio of 2.00 and a quick ratio of 1.30. Cresco Labs has a twelve month low of $1.02 and a twelve month high of $2.65.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.